BPC-157 Dosage: Routes, Ranges & the Human-Data Gap

How BPC-157 Was Dosed in Animal Studies

Almost the entire BPC-157 dosing record is preclinical. The peptide's identity, chemistry and proposed nitric-oxide and VEGF healing mechanism are covered in the companion BPC-157 healing research review; this page stays on the narrower question of how it was actually administered. Across the rodent corpus — which spans tendon, ligament, muscle, vascular and pharmacokinetic studies — four administration routes recur.^[1][2][3][8]

• Intraperitoneal (IP) injection. The most common route in the Zagreb injury models. In the rat Achilles-tendon-transection study, the peptide was given once daily intraperitoneally at 10 micrograms, 10 nanograms or 10 picograms per kilogram of body weight.^[2]
• Per-oral, in drinking water. The rat medial-collateral-ligament study delivered the peptide in the drinking water at 0.16 micrograms per millilitre (about 12 ml per rat per day) as an alternative to injection.^[1]
• Topical cream. The same ligament study also applied it locally as a thin cream layer (1.0 microgram dissolved per gram of neutral cream) at the injury site, and the muscle-crush study used a comparable topical-cream arm.^[1][3]
• Intravenous and intramuscular. The first dedicated pharmacokinetic study dosed rats and beagle dogs by single intravenous and single or repeated intramuscular injection, reporting an elimination half-life under 30 minutes and intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs.^[4]

Reviews that summarize the whole corpus describe the effective magnitudes as broadly on the order of micrograms to nanograms per kilogram — most often cited around 10 µg/kg and 10 ng/kg — rather than as a single standardized dose.^[5][6] Exact figures were not reported uniformly across every study, and the units are not directly comparable between routes (per-kilogram injections versus per-millilitre drinking water versus per-gram cream). Critically, these are rodent and canine figures; the reviews are explicit that they do not translate cleanly onto a human milligram scale, and this page makes no attempt to convert them.^[9]

The Small Human Dosing Record

The human record is small. FDA's July 2026 briefing document lists five human studies: two placebo-controlled studies in which BPC-157 was given as an enema, reported only as meeting abstracts in 2002–2005, and three uncontrolled pilot reports by Lee and colleagues from 2021, 2024 and 2025.^[11] The most recent, by Lee and Burgess, is a two-subject intravenous pilot in healthy adults, published in 2025 and indexed at PMID 40131143.^[7]

The study administered two consecutive-day intravenous infusions to two healthy adult participants — ascending from 10 mg on day 1 to 20 mg on day 2 — as a safety-and-tolerability assessment, with no efficacy endpoint. With only two participants it cannot characterise rare adverse events, dose-response, or human pharmacokinetics; what it adds is a first published intravenous safety touchpoint.^[7]

For research-context framing, that two-day ascending infusion to 20 mg is one of very few human exposures in the BPC-157 record, and none of the five studies set a dose. It is not a validated human dose, not a sustained-dosing regimen, and not a route comparison. Any source presenting a specific milligram-per-day human BPC-157 schedule is extrapolating well beyond these small reports.

Reconstitution & Handling (Research Use)

Because there is no human dose to describe, the only handling context this page provides is in-vitro laboratory handling of the research vial — not an administration protocol. BPC-157 ships as a lyophilized powder in a sealed vial, and the standard laboratory pattern is straightforward:

• Storage of the lyophilized vial. Held at 2–8 degrees Celsius and protected from light; frozen for longer-term storage, avoiding repeated fridge-to-bench temperature cycling.
• Reconstitution. Reconstituted with bacteriostatic water at the volume dictated by the research protocol, adding the diluent down the inner wall of the vial and letting it dissolve passively rather than shaking. The reconstitution calculator documents the concentration math (mass in the vial divided by diluent volume gives the label concentration).
• Post-reconstitution storage. Held at 2–8 degrees Celsius and used within the research-protocol window.

This describes the format and stability of the research vial and the arithmetic of label concentration; it is not a dosing instruction. The concentration a lab reconstitutes to is a handling choice, and the controlling reference for what is done with the reconstituted material is the investigator's own approved research protocol. BPC-157 is supplied strictly for in-vitro laboratory research and is not framed for human or veterinary use.

Why There Is No Established Human Dose

Four structural features of the evidence base explain why no validated human BPC-157 dose exists.

• The corpus is preclinical and single-group-dominated. The large majority of BPC-157 studies are rodent injury models, and a substantial share originate from one research group in Zagreb. Independent 2025 reviews summarising the literature reach the same conclusion — the peptide remains investigational, with the preclinical signal outpacing the human evidence.^[9][10]
• No completed human efficacy RCT has been published. Early-2000s papers describe BPC-157 (as Pliva's PL-14736 / PLD-116) entering clinical trials for inflammatory bowel disease, but no completed efficacy randomised controlled trial from that development program has appeared in the peer-reviewed literature.^[1] Its two placebo-controlled enema studies were reported only as meeting abstracts.^[11] That history is a development footnote, not evidence of an established dose.
• There is no human pharmacokinetic profile. Half-life, distribution, and route-specific bioavailability in humans are not characterised; the only dedicated pharmacokinetic work is the rat-and-dog study, which reported an elimination half-life under 30 minutes.^[4] Rodent per-kilogram figures cannot be scaled to a human milligram dose on that basis.
• It is not approved. BPC-157 is not approved as a medicine by any regulator, and recent independent reviews additionally flag that its long-term human safety is simply unknown.^[10] In July 2026 an FDA advisory committee voted 8–6, with 1 abstention, to recommend BPC-157 for the 503A bulks list for ulcerative colitis, against the advice of FDA's own reviewers. The vote is non-binding, and FDA had taken no final action as of 7 October 2026; see the FDA peptide reclassification overview.^[12]

The through-line is consistent with the rest of this page: a real and reproducible preclinical dosing record, five small human studies with no dose-finding work, and no basis for a validated human dose. Sources publishing specific human "BPC-157 protocols" are going beyond what the literature supports.

BPC-157 Research-Use Supply & Format

For research use, BPC-157 is supplied as a 10 mg lyophilized vial with cold-chain handling, reconstituted with bacteriostatic water for in-vitro work and with the active lot reference confirmed before dispatch — a format that mirrors how investigators handled the peptide in the animal-model literature, with no human-use framing attached.

The BPC-157 10mg research vial page documents the catalog format, current pricing, COA status and dispatch windows. Labs running BPC-157 alongside thymosin beta-4 / TB-500 typically reference the BPC-157 + TB-500 blend vial and the BPC-157 vs TB-500 comparison; the parallel dosing questions for that peptide are covered in the TB-500 dosage reference. Each BPC-157 research vial is supplied at >99% HPLC purity, and the standard reconstitution math sits in the reconstitution calculator.